LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

LLY

884.96

-0.04%↓

NVO

141.87

+0.6%↑

UNH

482.42

-0.43%↓

JNJ

148.65

+0.6%↑

MRK

130.24

+0.4%↑

Search

Biogen Inc

Closed

Sector Healthcare

223.75 -0.86

Overview

Share price change

24h

Current

Min

222.63

Max

224.22

Key metrics

By Trading Economics

Income

144M

393M

Sales

-96M

2.3B

P/E

Sector Avg

25.742

23.904

EPS

3.67

Profit margin

17.179

Employees

7,570

EBITDA

29M

682M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+26.36 upside

Dividends

By Dow Jones

Next Earnings

23 lip 2024

Market Stats

By TradingEconomics

Market Cap

-177M

34B

Previous open

224.61

Previous close

223.75

News Sentiment

By Acuity

85%

15%

331 / 369 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Biogen Inc Chart

Related News

7 sie 2023, 12:03 UTC

Major Market Movers

Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback

29 maj 2024, 15:56 UTC

Earnings
Acquisitions, Mergers, Takeovers

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

4 paź 2023, 17:55 UTC

Acquisitions, Mergers, Takeovers

Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment? -- IBD

1 wrz 2023, 15:23 UTC

Acquisitions, Mergers, Takeovers

Why Amgen's $28 Billion Merger News Also Bodes Well For Pfizer, Biogen -- IBD

25 lip 2023, 20:03 UTC

Earnings

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25 lip 2023, 15:41 UTC

Top News

A Surprising Beneficiary of New Alzheimer's Drugs: GE HealthCare -- Heard on the Street -- WSJ

25 lip 2023, 14:21 UTC

Earnings

Biogen Stock Plummets On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates -- IBD

25 lip 2023, 13:25 UTC

Earnings

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

25 lip 2023, 13:02 UTC

Earnings

Biogen Tops Second-Quarter Estimates With Alzheimer's Drug Not Yet Profitable -- IBD

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

26.36% upside

12 Months Forecast

Average 283.05 USD  26.36%

High 342 USD

Low 200 USD

Based on 25 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

25 ratings

19

Buy

6

Hold

0

Sell

Technical Score

By Trading Central

220.375 / 225.43Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

331 / 369 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.